Ziv-aflibercept and bevacizumab for exudative age-related macular degeneration: A retrospective comparison of clinical outcomes and cost at 1 year
PURPOSE: The purpose of this study was to compare intravitreal ziv-aflibercept (IVZ) monotherapy to intravitreal bevacizumab (IVB) monotherapy in patients with exudative age-related macular degeneration (eAMD). MATERIALS AND METHODS: Patients with treatment-naïve eAMD treated with pro re nata (PRN)...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | Taiwan Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.e-tjo.org/article.asp?issn=2211-5056;year=2020;volume=10;issue=4;spage=289;epage=293;aulast=Singh |
id |
doaj-89faf88e886b45a982a059191cec13bf |
---|---|
record_format |
Article |
spelling |
doaj-89faf88e886b45a982a059191cec13bf2020-12-02T13:13:48ZengWolters Kluwer Medknow PublicationsTaiwan Journal of Ophthalmology2211-50562211-50722020-01-0110428929310.4103/tjo.tjo_3_20Ziv-aflibercept and bevacizumab for exudative age-related macular degeneration: A retrospective comparison of clinical outcomes and cost at 1 yearSumit Randhir SinghRavi ParikhYoichi SakuradaBhushan UplanchiwarAhmad MansourAbhilash GoudYasha S ModiJay ChhablaniPURPOSE: The purpose of this study was to compare intravitreal ziv-aflibercept (IVZ) monotherapy to intravitreal bevacizumab (IVB) monotherapy in patients with exudative age-related macular degeneration (eAMD). MATERIALS AND METHODS: Patients with treatment-naïve eAMD treated with pro re nata (PRN) monotherapy of IVZ (1.25 mg/0.05 ml) or IVB (1.25 mg/0.05 ml) with a minimum follow-up of 12 months were retrospectively analyzed. Study outcomes included change in best-corrected visual acuity (BCVA), central macular thickness, mean number of injections, and total medication cost in both the groups at 12 months. RESULTS: Forty-seven eyes (IVZ, 18/47 [38.3%] and IVB, 29/47 [61.7%]) from 47 treatment-naive patients were included. The change in BCVA for patients receiving IVZ was from 0.61 ± 0.33 logarithm of the minimum angle of resolution (Snellen 20/81; range: 20/38–20/174) to 0.45 ± 0.31 (Snellen 20/56; range: 20/27–20/115) at 1 year (P = 0.02). The total number of injections needed to achieve the resolution of intraretinal or subretinal fluid was 2.6 ± 1.4 and 3.5 ± 1.3 for IVZ and IVB, respectively (P = 0.029). Direct medication cost of IVZ and IVB in our cohort on PRN basis was an average of US$78 (2.6 × US$30) and US$175 (3.5 × US$50), respectively, through 1 year. CONCLUSION: IVZ-PRN monotherapy resulted in improved visual acuity, reduced treatment burden, and reduced direct medication cost in comparison to IVB-PRN monotherapy through 1 year.http://www.e-tjo.org/article.asp?issn=2211-5056;year=2020;volume=10;issue=4;spage=289;epage=293;aulast=Singhage-related macular degenerationantivascular endothelial growth factorbevacizumabziv-aflibercept |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sumit Randhir Singh Ravi Parikh Yoichi Sakurada Bhushan Uplanchiwar Ahmad Mansour Abhilash Goud Yasha S Modi Jay Chhablani |
spellingShingle |
Sumit Randhir Singh Ravi Parikh Yoichi Sakurada Bhushan Uplanchiwar Ahmad Mansour Abhilash Goud Yasha S Modi Jay Chhablani Ziv-aflibercept and bevacizumab for exudative age-related macular degeneration: A retrospective comparison of clinical outcomes and cost at 1 year Taiwan Journal of Ophthalmology age-related macular degeneration antivascular endothelial growth factor bevacizumab ziv-aflibercept |
author_facet |
Sumit Randhir Singh Ravi Parikh Yoichi Sakurada Bhushan Uplanchiwar Ahmad Mansour Abhilash Goud Yasha S Modi Jay Chhablani |
author_sort |
Sumit Randhir Singh |
title |
Ziv-aflibercept and bevacizumab for exudative age-related macular degeneration: A retrospective comparison of clinical outcomes and cost at 1 year |
title_short |
Ziv-aflibercept and bevacizumab for exudative age-related macular degeneration: A retrospective comparison of clinical outcomes and cost at 1 year |
title_full |
Ziv-aflibercept and bevacizumab for exudative age-related macular degeneration: A retrospective comparison of clinical outcomes and cost at 1 year |
title_fullStr |
Ziv-aflibercept and bevacizumab for exudative age-related macular degeneration: A retrospective comparison of clinical outcomes and cost at 1 year |
title_full_unstemmed |
Ziv-aflibercept and bevacizumab for exudative age-related macular degeneration: A retrospective comparison of clinical outcomes and cost at 1 year |
title_sort |
ziv-aflibercept and bevacizumab for exudative age-related macular degeneration: a retrospective comparison of clinical outcomes and cost at 1 year |
publisher |
Wolters Kluwer Medknow Publications |
series |
Taiwan Journal of Ophthalmology |
issn |
2211-5056 2211-5072 |
publishDate |
2020-01-01 |
description |
PURPOSE: The purpose of this study was to compare intravitreal ziv-aflibercept (IVZ) monotherapy to intravitreal bevacizumab (IVB) monotherapy in patients with exudative age-related macular degeneration (eAMD).
MATERIALS AND METHODS: Patients with treatment-naïve eAMD treated with pro re nata (PRN) monotherapy of IVZ (1.25 mg/0.05 ml) or IVB (1.25 mg/0.05 ml) with a minimum follow-up of 12 months were retrospectively analyzed. Study outcomes included change in best-corrected visual acuity (BCVA), central macular thickness, mean number of injections, and total medication cost in both the groups at 12 months.
RESULTS: Forty-seven eyes (IVZ, 18/47 [38.3%] and IVB, 29/47 [61.7%]) from 47 treatment-naive patients were included. The change in BCVA for patients receiving IVZ was from 0.61 ± 0.33 logarithm of the minimum angle of resolution (Snellen 20/81; range: 20/38–20/174) to 0.45 ± 0.31 (Snellen 20/56; range: 20/27–20/115) at 1 year (P = 0.02). The total number of injections needed to achieve the resolution of intraretinal or subretinal fluid was 2.6 ± 1.4 and 3.5 ± 1.3 for IVZ and IVB, respectively (P = 0.029). Direct medication cost of IVZ and IVB in our cohort on PRN basis was an average of US$78 (2.6 × US$30) and US$175 (3.5 × US$50), respectively, through 1 year.
CONCLUSION: IVZ-PRN monotherapy resulted in improved visual acuity, reduced treatment burden, and reduced direct medication cost in comparison to IVB-PRN monotherapy through 1 year. |
topic |
age-related macular degeneration antivascular endothelial growth factor bevacizumab ziv-aflibercept |
url |
http://www.e-tjo.org/article.asp?issn=2211-5056;year=2020;volume=10;issue=4;spage=289;epage=293;aulast=Singh |
work_keys_str_mv |
AT sumitrandhirsingh zivafliberceptandbevacizumabforexudativeagerelatedmaculardegenerationaretrospectivecomparisonofclinicaloutcomesandcostat1year AT raviparikh zivafliberceptandbevacizumabforexudativeagerelatedmaculardegenerationaretrospectivecomparisonofclinicaloutcomesandcostat1year AT yoichisakurada zivafliberceptandbevacizumabforexudativeagerelatedmaculardegenerationaretrospectivecomparisonofclinicaloutcomesandcostat1year AT bhushanuplanchiwar zivafliberceptandbevacizumabforexudativeagerelatedmaculardegenerationaretrospectivecomparisonofclinicaloutcomesandcostat1year AT ahmadmansour zivafliberceptandbevacizumabforexudativeagerelatedmaculardegenerationaretrospectivecomparisonofclinicaloutcomesandcostat1year AT abhilashgoud zivafliberceptandbevacizumabforexudativeagerelatedmaculardegenerationaretrospectivecomparisonofclinicaloutcomesandcostat1year AT yashasmodi zivafliberceptandbevacizumabforexudativeagerelatedmaculardegenerationaretrospectivecomparisonofclinicaloutcomesandcostat1year AT jaychhablani zivafliberceptandbevacizumabforexudativeagerelatedmaculardegenerationaretrospectivecomparisonofclinicaloutcomesandcostat1year |
_version_ |
1724406217612197888 |